# India Allergy Immunotherapy Market

> India Allergy Immunotherapy Market Research Report: By Type (Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy), By Product (Allergen Extracts, Conventional Immunotherapy, Biologics), By Indication (Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, Food Allergies) andBy Patient Type (Pediatric, Adult, Geriatric)- Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.43%
- **2018:** $ 212.8 Million
- **2024:** $ 113.2 Million
- **2035:** $ 305.08 Million
- **Key Players:** Allergan (US), Boehringer Ingelheim (DE), Merck Group (DE), Novartis (CH), Stallergenes Greer (GB), Aimmune Therapeutics (US), ALK-Abello (DK), HollisterStier Allergy (US)

**Report ID:** MRFR/HC/54531-HCR · **Pages:** 200 · **Author:** Nidhi Mandole · **Last Updated:** May 12, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-allergy-immunotherapy-market-56297

---

## Market Summary

**India Allergy Immunotherapy Market Overview****:**

**As per MRFR analysis, the India Allergy Immunotherapy Market Size was estimated at 212.8 (USD Million) in 2023. The India Allergy Immunotherapy Market Industry is expected to grow from 228.4(USD Million) in 2024 to 914.8 (USD Million) by 2035. The India Allergy Immunotherapy Market CAGR (growth rate) is expected to be around 13.445% during the forecast period (2025 - 2035).**

**Key India Allergy Immunotherapy Market Trends Highlighted**

The India Allergy Immunotherapy Market is increasing significantly as a result of a variety of core market drivers. Among the Indian populace, the increasing prevalence of allergic disorders, including allergic rhinitis, asthma, and dietary allergies, is one of the primary factors. There is a greater awareness and demand for effective treatment options as a result of the increasing incidence. Furthermore, the increasing prevalence of environmental allergies in India is further exacerbated by the changing lifestyle patterns and urbanization that are propelling the demand for allergy immunotherapy. Recent advancements in treatment methods and increased investment in research and development will enable the exploration of opportunities in this market. Healthcare initiatives that promote innovative treatments have been promoted by the Indian government, which may result in more accessible immunotherapy options. There is also the potential for expansion in rural areas, where there is a lack of awareness regarding allergy management. This presents an opportunity to introduce and educate a broader audience on immunotherapy options. Personalized medicine has become increasingly popular in allergy treatment in recent years, which is indicative of a substantial trend in the India Allergy Immunotherapy Market. By customizing treatments to the unique allergic profiles of each patient, personalized immunotherapy seeks to optimize the efficacy of therapies.Another noteworthy development is the expanding use of digital health tools, such as telemedicine and mobile health applications, to enhance patient access and adherence to immunotherapy. All of these trends collectively indicate a gradual transition to more innovative, patient-centered approaches in allergy management throughout India.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Allergy Immunotherapy Market Drivers**

Rising Incidence of Allergies and Asthma

In India, the prevalence of allergies and asthma has been on the rise, with the Health Ministry reporting that around 20-30% of the population suffers from some form of allergic condition. This increasing incidence can be attributed to urbanization, pollution levels, and lifestyle changes. The Indian Society of Allergy, Asthma, and Immunology indicates that asthma affects nearly 26 million individuals across the country. As more people seek effective treatments, the India Allergy Immunotherapy Market Industry is expected to grow, driven by the demand for innovative and personalized immunotherapy solutions.Major pharmaceutical companies like Novartis and Allergan are investing heavily in Research and Development to develop targeted therapies, further driving market growth and creating an ecosystem that fosters advancements in allergen desensitization therapies.

Government Initiatives and Support

The Indian government has recognized the growing burden of allergies and has initiated various policies to promote better healthcare solutions. The National Health Mission aims to create awareness about allergic diseases and enhance the quality of care provided to patients. In recent years, the government has also supported public-private partnerships and funding for Research and Development in the healthcare sector. For example, the allocation of funds exceeding USD 1.2 billion in the last financial year for health services reflects a commitment to addressing health challenges, including allergies.This supportive environment drives growth in the India Allergy Immunotherapy Market Industry, paving the way for innovative therapies and better access to treatment.

Advancements in Immunotherapy Techniques

Recent advancements in immunotherapy techniques are significantly influencing the India Allergy Immunotherapy Market Industry. Technologies such as sublingual immunotherapy, which is less invasive and more patient-friendly, have gained traction in metropolitan areas. The Indian Association of Allergy and Clinical Immunology indicates that these advancements are expected to reduce treatment time and improve patient compliance rates, leading to better health outcomes for allergy sufferers.Many established pharmaceutical companies, including GlaxoSmithKline and Merck, are investing in the development of novel immunotherapy techniques tailored to the diverse Indian population, which is likely to accelerate market growth in the coming years.

Growing Awareness and Patient Education

There has been a marked increase in awareness regarding allergy immunotherapy among the Indian populace, driven by educational campaigns from various health organizations and government initiatives. The Lung Care Foundation highlights that enhanced public knowledge can lead to prompt recognition of allergy symptoms, resulting in earlier diagnosis and treatment. Surveys indicate that almost 60% of individuals suffering from allergies are now familiar with immunotherapy options available in India.This rising awareness leads to a greater demand for allergy treatments and thereby propels the growth of the India Allergy Immunotherapy Market Industry as patients actively seek allergen-specific therapies.

**India Allergy Immunotherapy Market Segment Insights****:**

**Allergy Immunotherapy Market Type Insights**

The India Allergy Immunotherapy Market is experiencing a significant transformation as it expands to meet the growing demand for effective allergy treatments. This market is broadly categorized into various types, with Subcutaneous Immunotherapy, Sublingual Immunotherapy, and Oral Immunotherapy being the main types of treatment modalities. Each of these types plays a vital role in addressing the unique needs of patients suffering from allergic conditions. Subcutaneous Immunotherapy has traditionally been a dominant method due to its long-established efficacy in providing robust immunological responses, which help to mitigate allergic reactions over time.This approach is often preferred for patients with severe allergies, as it allows for tailored doses administered through injections. On the other hand, Sublingual Immunotherapy has been gaining traction due to its ease of use and the convenience it offers. Administered under the tongue, this method is particularly appealing to patients who may be hesitant about needles or frequent visits to healthcare facilities. Furthermore, Oral Immunotherapy is emerging as an innovative and patient-friendly alternative, especially for allergies related to food.This type of therapy aims to desensitize individuals gradually by introducing the allergenic food in controlled amounts. The growing awareness of allergic conditions and the need for effective management strategies are vital drivers of the India Allergy Immunotherapy Market. The Indian government has also been promoting better healthcare access, thereby encouraging the adoption of allergy immunotherapy treatments. As awareness among both healthcare providers and patients rises, these types of immunotherapy are likely to see increased demand in the coming years, leading to a more diverse range of treatment options available in the market, thus improving patient outcomes across the region.Overall, the growing prevalence of allergic disorders in India, supported by ongoing research and development, positions all types of allergy immunotherapy as essential components in the global fight against allergic conditions. Each type contributes uniquely to the patient experience, thus collectively shaping the future landscape of allergy treatment in India.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Allergy Immunotherapy Market Product Insights**

The India Allergy Immunotherapy Market represents a dynamic sector within the broader healthcare landscape, driven by rising awareness about allergy treatments and increasing incidence of allergic diseases. The product segment comprises various therapeutic approaches, notably Allergen Extracts, Conventional Immunotherapy, and Biologics. Allergen Extracts play a crucial role in the treatment of allergic conditions, offering patients a personalized approach to immunotherapy. Conventional Immunotherapy continues to be a longstanding method, addressing a range of allergens and helping patients build tolerance over time.Meanwhile, Biologics are emerging as a significant innovation, offering targeted therapies that enhance treatment efficacy for individuals with severe allergic responses. The growth of this segment is supported by favorable regulatory trends and heightened investment in Research and Development within the pharmaceutical industry, making it an attractive area for stakeholders. As the India Allergy Immunotherapy Market evolves, these product offerings are expected to address unmet needs in the healthcare system, presenting new opportunities for both patients and providers.The market's potential is underscored by increasing investments and technological advancements, paving the way for more effective allergy management solutions.

**Allergy Immunotherapy Market Indication Insights**

The India Allergy Immunotherapy Market is experiencing significant growth, particularly within the Indication segment, which includes Allergic Rhinitis, Allergic Asthma, Atopic Dermatitis, and Food Allergies. Allergic Rhinitis, often triggered by environmental factors such as pollen and dust, affects a substantial part of the population, leading to increased demand for treatment options. Concurrently, Allergic Asthma remains a prominent respiratory condition in India, with rising pollution levels further exacerbating symptoms and creating a notable need for effective immunotherapy options.Atopic Dermatitis, a chronic skin condition, is increasingly recognized for its prevalence in both children and adults, driving awareness and advocacy for innovative treatment methodologies. Furthermore, Food Allergies represent a growing concern, particularly among children, as awareness regarding allergic reactions to common foods continues to rise. This segment not only underscores the urgent public health implications but also highlights opportunities for pharmaceutical advancements aimed at improving patient quality of life. Collectively, these indications illustrate the multifaceted nature of the India Allergy Immunotherapy Market and the essential role each plays in shaping treatment strategies and market dynamics.

**Allergy Immunotherapy Market Patient Type Insights**

The India Allergy Immunotherapy Market, with its diverse Patient Type segments, offers a comprehensive landscape for addressing allergy-related conditions across different age groups. The Pediatric segment is particularly significant, as early intervention in children can lead to better long-term outcomes in managing allergies. With the increasing prevalence of allergic diseases among children, this segment plays a crucial role in shaping future market dynamics. The Adult segment holds a major share of the market, as adults are often more exposed to allergens due to environmental factors and lifestyle choices, making them susceptible to various allergies.This group is keen on seeking effective solutions, thereby driving demand in the allergy immunotherapy space. On the other hand, the Geriatric segment is gaining attention, considering the rising elderly population in India that faces heightened vulnerability to allergies due to age-related immune decline. As healthcare awareness increases globally, the focus on tailored treatment options for these diverse patient types becomes essential for market growth, presenting numerous opportunities for companies within the India Allergy Immunotherapy Market industry.The market statistics highlight a trend toward personalized medicine that can cater to the unique needs of each group, ultimately contributing to improved patient outcomes.

**India Allergy Immunotherapy Market Key Players and Competitive Insights****:**

The India Allergy Immunotherapy Market has been experiencing significant growth, driven by an increasing prevalence of allergic conditions and a growing awareness of allergen immunotherapy among consumers and healthcare providers. As the market expands, various players are entering the arena, enhancing competition through innovative therapies, product offerings, and improved patient access. Organizations in this sector are focusing on expanding their footprints, forging partnerships, investing in research and development for enhanced treatment efficacy, and navigating regulatory landscapes. As such, understanding the competitive dynamics, market positioning, and product strategies of key players becomes vital for stakeholders in capitalizing on opportunities within this emerging market.Merck, a global leader in pharmaceutical and vaccine development, has a notable presence in the India Allergy Immunotherapy Market. The company has leveraged its extensive research capabilities and established relations within the healthcare sector to offer innovative solutions for allergy management. Merck's strengths lie in its robust portfolio of allergy immunotherapy products, created through years of research and development. The company's dedication to educating healthcare professionals and patients about the benefits of immunotherapy underlines its commitment to improving health outcomes in allergic individuals. Merck also emphasizes local collaborations that enhance its operational effectiveness and market reach, positioning itself favorably to cater to the growing demand for allergy treatments in India.Stallergenes Greer possesses a strong foothold in the India Allergy Immunotherapy Market, focusing on a range of allergy management solutions, including sublingual and injectable immunotherapy products. The company is recognized for its commitment to research and its innovative approaches to allergen formulation, which cater specifically to regional needs. Stallergenes Greer has actively pursued strategic partnerships and alliances to bolster its market presence in India, enhancing its product availability and distribution networks. Key products offered by Stallergenes Greer include specific immunotherapy solutions that address common allergens prevalent in the Indian population. The company has also engaged in mergers and acquisitions to streamline its operations and broaden its product line, thus reinforcing its position as a significant player within the allergy immunotherapy landscape in India.

**Key Companies in the India Allergy Immunotherapy Market Include:**

Merck

Stallergenes Greer

S interrogative S A

Aimmune Therapeutics

UCB

Boehringer Ingelheim

Regeneron Pharmaceuticals

Novartis

Sheller S.A.

Vaccine Technologies

Diater

ImmunoCAP

Allergan

**India Allergy Immunotherapy Market Industry Developments**

_The India Allergy Immunotherapy Market has seen several significant developments recently. In July 2023, Merck launched a new allergy immunotherapy product aimed at enhancing treatment options for allergic rhinitis, targeting a growing patient population. Additionally, in September 2023, Stallergenes Greer announced a collaboration with local clinics in India to increase awareness and accessibility of their sublingual immunotherapy products. The market landscape is further shaped by the entry of Aimmune Therapeutics and UCB, which have introduced innovative therapies catering to food allergies. In terms of mergers and acquisitions, Regeneron Pharmaceuticals completed an acquisition of a biotechnology firm specializing in allergic diseases in June 2023, reinforcing its commitment to advancing treatments in this field. The overall growth in the allergy immunotherapy market in India is impacted by increasing allergic conditions, with a reported market valuation of over USD 600 million as of early 2023, driven by heightened awareness and demand for effective long-term solutions. Noteworthy trends include a rise in research initiatives focusing on personalized medicine and the integration of digital health solutions to improve patient management in allergy therapies._

**India Allergy Immunotherapy Market Segmentation Insights**

**Allergy Immunotherapy Market Type****Outlook**

**Subcutaneous Immunotherapy**

**Sublingual Immunotherapy**

**Oral Immunotherapy**

**Allergy Immunotherapy Market Product****Outlook**

**Allergen Extracts**

**Conventional Immunotherapy**

**Biologics**

**Allergy Immunotherapy Market Indication****Outlook**

**Allergic Rhinitis**

**Allergic Asthma**

**Atopic Dermatitis**

**Food Allergies**

**Allergy Immunotherapy Market Patient Type****Outlook**

**Pediatric**

**Adult**

**Geriatric**

****

## Market Drivers

### Rising Awareness of Allergies

The increasing awareness regarding allergies and their management is a pivotal driver for the India [Allergy Immunotherapy](https://www.marketresearchfuture.com/reports/allergy-immunotherapy-market-1517) Market. As more individuals recognize the symptoms and implications of allergic reactions, there is a growing demand for effective treatment options. Public health campaigns and educational initiatives have contributed to this awareness, leading to a rise in consultations with healthcare professionals. Consequently, the market for immunotherapy is expanding, as patients seek long-term solutions rather than temporary relief. In 2025, the prevalence of allergic rhinitis in India was reported to be around 20%, indicating a substantial patient base for immunotherapy. This trend suggests that as awareness continues to grow, the India Allergy Immunotherapy Market is likely to experience significant growth in the coming years.

### Increase in Allergic Conditions

The rising incidence of allergic conditions in India is a critical driver for the India Allergy Immunotherapy Market. Factors such as urbanization, environmental pollution, and lifestyle changes are contributing to the growing prevalence of allergies. Reports indicate that approximately 30% of urban Indian populations suffer from some form of allergy, creating a substantial demand for effective treatment options. This trend is prompting healthcare providers to explore immunotherapy as a viable long-term solution. As the number of individuals seeking treatment for allergies continues to rise, the India Allergy Immunotherapy Market is poised for significant expansion, with an increasing number of patients opting for immunotherapy.

### Growing Investment in Healthcare

The surge in investment in the healthcare sector is a notable driver for the India Allergy Immunotherapy Market. With the increasing focus on healthcare infrastructure and the rising demand for specialized treatments, investors are channeling funds into allergy research and immunotherapy development. In 2025, the healthcare investment in India was projected to exceed USD 10 billion, with a portion allocated specifically for allergy-related treatments. This influx of capital is likely to foster innovation and enhance the availability of immunotherapy options. As a result, the India Allergy Immunotherapy Market is expected to benefit from improved treatment modalities and increased patient access to advanced therapies.

### Government Initiatives and Support

Government initiatives aimed at improving healthcare access and allergy management are significantly influencing the India Allergy Immunotherapy Market. Policies promoting research and development in allergy treatments, along with subsidies for immunotherapy, are encouraging healthcare providers to adopt these therapies. The Indian government has recognized the rising burden of allergic diseases and is actively working to enhance healthcare infrastructure. In 2025, the government allocated substantial funds for allergy research, which is anticipated to bolster the market. This supportive regulatory environment is likely to facilitate the growth of the India Allergy Immunotherapy Market, making advanced treatments more accessible to the population.

### Technological Innovations in Treatment

Technological advancements in the field of allergy immunotherapy are transforming the India Allergy Immunotherapy Market. Innovations such as sublingual immunotherapy and advanced allergen extracts are enhancing treatment efficacy and patient compliance. These technologies allow for more personalized treatment plans, catering to the specific needs of patients. Furthermore, the integration of digital health solutions, including mobile applications for tracking symptoms and treatment progress, is gaining traction. In 2025, the market for allergy immunotherapy in India was projected to reach USD 300 million, driven by these technological innovations. As these advancements continue to evolve, they are expected to play a crucial role in shaping the future landscape of the India Allergy Immunotherapy Market.

## Future Outlook

The India Allergy Immunotherapy Market is projected to grow at a 9.43% CAGR from 2024 to 2035, driven by increasing allergy prevalence, technological advancements, and rising healthcare awareness.

**New opportunities:**

- Expansion of personalized immunotherapy solutions for diverse allergens. Development of mobile health applications for patient monitoring and engagement. Investment in advanced manufacturing technologies for cost-effective production.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in [allergy treatment](https://www.marketresearchfuture.com/reports/allergy-treatment-market-11156) solutions.

## Segment Insights

### By Application: Allergic Rhinitis (Largest) vs. Allergic Asthma (Fastest-Growing)

In the India Allergy Immunotherapy Market, Allergic Rhinitis holds the largest share due to its widespread prevalence among the population. The increasing incidence of this condition has made it a focal point for healthcare providers and pharmaceutical companies. Following closely, Allergic Asthma is experiencing significant growth, attributed to heightened awareness and better diagnostic practices, leading to a surge in demand for effective immunotherapy solutions. Other conditions like Insect Allergy, Food Allergy, and Atopic Dermatitis remain important but lack the same level of market penetration as these two segments.

Allergic Rhinitis: Dominant vs. Allergic Asthma: Emerging

Allergic Rhinitis currently dominates the India Allergy Immunotherapy Market due to its high incidence and broad public awareness. It has a well-established treatment protocol and a wide range of available therapies, making it accessible for patients. In contrast, Allergic Asthma is rapidly emerging as a critical segment with increasing attention from healthcare professionals, spurred by rising asthma diagnoses. This shift is driven by enhanced education on the condition, improved therapeutic options, and increased advocacy for early intervention. As treatment modalities evolve, Allergic Asthma is poised to capture a significant share of the market, compelling companies to innovate and enhance their offerings in this area.

### By Type of Immunotherapy: Subcutaneous Immunotherapy (Largest) vs. Sublingual Immunotherapy (Fastest-Growing)

In the India Allergy Immunotherapy Market, Subcutaneous Immunotherapy holds the largest market share, primarily due to its long-established efficacy and wide acceptance among healthcare providers and patients. This segment benefits from a proven track record, making it the preferred choice for many allergists when designing treatment plans for patients with allergic conditions. Meanwhile, Sublingual Immunotherapy, characterized by its ease of administration and patient-friendly approach, is rapidly gaining traction in the market, appealing particularly to those who prefer alternatives to injections.

Subcutaneous Immunotherapy (Dominant) vs. Sublingual Immunotherapy (Emerging)

Subcutaneous Immunotherapy is the dominant player in the market, offering a powerful treatment option for severe allergic reactions. Patients receive allergen extracts through periodic injections, leading to long-term desensitization. Its established safety profile and efficacy contribute to its strong market position. In contrast, Sublingual Immunotherapy represents an emerging approach, where patients place allergen tablets or drops under their tongues. This method is gaining popularity due to its convenience, especially among individuals hesitant about needles. As awareness increases and more allergens are approved for this method, it is poised to capture a larger share of the market.

### By Patient Demographics: Pediatric Patients (Largest) vs. Adult Patients (Fastest-Growing)

In the India Allergy Immunotherapy Market, the distribution of patient demographics highlights a significant prevalence among pediatric patients, who account for the largest share. This demographic's sensitivity to allergens and the increasing awareness of allergic conditions contribute to their domination in this sector. Following them, adult patients are rapidly gaining traction, reflecting a growing recognition of the benefits of immunotherapy for allergy management. The trend towards treating allergies is experiencing considerable momentum, driven by rising incidences of allergic reactions across all age groups. The adult patient segment, in particular, is witnessing an upsurge due to lifestyle changes, increased exposure to allergens, and a greater willingness to seek specialized treatment. Thus, while pediatric patients remain a critical segment, adult patients are emerging robustly in this market.

Pediatric Patients (Dominant) vs. Geriatric Patients (Emerging)

Pediatric patients, characterized by a higher incidence of allergies and a robust response to immunotherapy, continue to hold a dominant position in the India Allergy Immunotherapy Market. Their early diagnosis and treatment opportunities have fostered a strong customer base. In contrast, geriatric patients represent an emerging demographic; aging-related susceptibility to allergies, coupled with a rising awareness about treatment options, is positioning them for growth. Geriatric demographics often face multiple health challenges, leading to a more intricate treatment landscape. As healthcare professionals increasingly recognize the importance of tailored immunotherapy solutions, the geriatric segment is expected to evolve, reflecting both increasing demand and a growing acceptance of allergy management within this age group.

### By Treatment Duration: Maintenance Treatment (Largest) vs. Induction Treatment (Fastest-Growing)

In the India Allergy Immunotherapy Market, the Treatment Duration segment is primarily dominated by Maintenance Treatment, which caters to the needs of patients requiring ongoing relief from allergy symptoms. This treatment strategy emphasizes a long-term management approach, allowing patients to build immunity over time. Induction Treatment, designed for initiating patients into immunotherapy, is growing rapidly as more individuals seek immediate relief and are introduced to long-term therapy benefits.

Maintenance Treatment (Dominant) vs. Induction Treatment (Emerging)

Maintenance Treatment in the India Allergy Immunotherapy Market is characterized by continuous administration to sustain the therapeutic effects of immunotherapy, making it essential for long-term allergy management. This treatment is crucial for chronic allergy sufferers, ensuring consistent symptom relief and a gradual buildup of immunity. In contrast, Induction Treatment serves as a crucial entry point into the therapeutic journey, attracting patients eager to address their conditions more rapidly. With the growing awareness of immunotherapy's benefits, Induction Treatment is gaining traction, highlighting its promising future in the market as patient uptake accelerates.

## Competitive Benchmarking

The India Allergy Immunotherapy Market is currently characterized by a dynamic competitive landscape, driven by increasing prevalence of allergic conditions and a growing awareness of immunotherapy as a viable treatment option. Key players such as Merck Group (DE), Novartis (CH), and ALK-Abello (DK) are actively shaping the market through strategic initiatives focused on innovation and regional expansion. Merck Group (DE) has been particularly aggressive in enhancing its product portfolio, while Novartis (CH) emphasizes partnerships to bolster its market presence. ALK-Abello (DK) appears to be concentrating on digital transformation to improve patient engagement and treatment adherence, collectively influencing the competitive environment towards a more integrated and patient-centric approach.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains, which is crucial in a market that is moderately fragmented. This localization strategy not only enhances operational efficiency but also allows for quicker response times to market demands. The competitive structure is shaped by the collective influence of these key players, who are leveraging their strengths to navigate the complexities of the market.
In January 2026, Merck Group (DE) announced the launch of a new line of allergy immunotherapy products tailored specifically for the Indian market. This strategic move is significant as it demonstrates Merck's commitment to addressing local needs and expanding its footprint in a rapidly growing segment. By customizing its offerings, Merck aims to enhance patient outcomes and solidify its competitive position.
In December 2025, Novartis (CH) entered into a strategic partnership with a leading Indian healthcare provider to enhance access to its immunotherapy treatments. This collaboration is likely to facilitate better distribution and patient education, thereby increasing the adoption of immunotherapy solutions. Such partnerships are essential in a market where awareness and accessibility remain challenges.
In November 2025, ALK-Abello (DK) launched a digital platform aimed at improving patient engagement and adherence to immunotherapy regimens. This initiative reflects a broader trend towards digitalization in healthcare, where technology is leveraged to enhance patient experiences and outcomes. By focusing on digital solutions, ALK-Abello is positioning itself as a forward-thinking player in the market.
As of February 2026, current competitive trends indicate a strong shift towards digitalization, sustainability, and the integration of AI in treatment protocols. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology, and supply chain reliability, underscoring the importance of adaptability in a rapidly changing market.

## Recent News & Developments

_The India Allergy Immunotherapy Market has seen several significant developments recently. In July 2023, Merck launched a new allergy immunotherapy product aimed at enhancing treatment options for allergic rhinitis, targeting a growing patient population. Additionally, in September 2023, Stallergenes Greer announced a collaboration with local clinics in India to increase awareness and accessibility of their sublingual immunotherapy products. The market landscape is further shaped by the entry of Aimmune Therapeutics and UCB, which have introduced innovative therapies catering to food allergies. In terms of mergers and acquisitions, Regeneron Pharmaceuticals completed an acquisition of a biotechnology firm specializing in allergic diseases in June 2023, reinforcing its commitment to advancing treatments in this field. The overall growth in the allergy immunotherapy market in India is impacted by increasing allergic conditions, with a reported market valuation of over USD 600 million as of early 2023, driven by heightened awareness and demand for effective long-term solutions. Noteworthy trends include a rise in research initiatives focusing on personalized medicine and the integration of digital health solutions to improve patient management in allergy therapies._

## Report Scope

Report Scope:

| Report Attribute/Metric Source: | Details |
| --- | --- |
| MARKET SIZE 2018 | 212.8(USD Million) |
| MARKET SIZE 2024 | 228.4(USD Million) |
| MARKET SIZE 2035 | 914.8(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 13.445% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Merck, Stallergenes Greer, S interrogative S A, Aimmune Therapeutics, UCB, Boehringer Ingelheim, Regeneron Pharmaceuticals, Novartis, Sheller S.A., Vaccine Technologies, Diater, ImmunoCAP, Allergan |
| SEGMENTS COVERED | Type, Product, Indication, Patient Type |
| KEY MARKET OPPORTUNITIES | Rising allergic disease prevalence, Increasing disposable income, Growing awareness of immunotherapy, Expansion of healthcare infrastructure, Enhanced regulatory support for therapies |
| KEY MARKET DYNAMICS | rising allergy prevalence, increasing awareness, supportive government policies, technological advancements, growing healthcare expenditure |
| COUNTRIES COVERED | India |

## Frequently Asked Questions

**Q: What is the current valuation of the India Allergy Immunotherapy Market?**
A: The market valuation was 113.2 USD Million in 2024.

**Q: What is the projected market size for the India Allergy Immunotherapy Market by 2035?**
A: The market is expected to reach 305.08 USD Million by 2035.

**Q: What is the expected CAGR for the India Allergy Immunotherapy Market during the forecast period?**
A: The expected CAGR for the market from 2025 to 2035 is 9.43%.

**Q: Which application segment has the highest valuation in the India Allergy Immunotherapy Market?**
A: The Allergic Rhinitis segment had a valuation range of 45.0 to 120.0 USD Million.

**Q: What are the key types of immunotherapy in the India Allergy Immunotherapy Market?**
A: The key types include Subcutaneous Immunotherapy, Sublingual Immunotherapy, Oral Immunotherapy, and Intranasal Immunotherapy.

**Q: Which patient demographic segment shows the highest market potential?**
A: The Adult Patients segment had a valuation range of 60.0 to 160.0 USD Million.

**Q: What is the valuation range for the Intranasal Immunotherapy segment?**
A: The Intranasal Immunotherapy segment is valued between 38.2 and 105.08 USD Million.

**Q: Who are the leading players in the India Allergy Immunotherapy Market?**
A: Key players include Allergan, Boehringer Ingelheim, Merck Group, and Novartis.

**Q: What is the valuation range for the Long-term Treatment segment?**
A: The Long-term Treatment segment is valued between 30.0 and 80.0 USD Million.

**Q: How does the market for Food Allergy immunotherapy compare to other segments?**
A: The Food Allergy segment had a valuation range of 10.0 to 25.0 USD Million, indicating lower market potential compared to others.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-allergy-immunotherapy-market-56297*